Last $58.58 USD
Change Today +0.04 / 0.07%
Volume 9.7M
MRK On Other Exchanges
Symbol
Exchange
New York
EN Paris
Sao Paulo
Frankfurt
As of 6:40 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by MERCK & CO. INC. (MRK) in the last 6 months

Announced 02/23/15
106.00M for NGM Biopharmaceuticals, Inc.
Merger/Acquisition

Merck & Co. Inc. (NYSE:MRK) agreed to acquire 15% stake in NGM Biopharmaceuticals, Inc. for approximately $110 million on February 23, 2015. Concurrently, Merck & Co. Inc. has entered into a five-year collaboration agreement with NGM Biopharmaceuticals Inc. to research and develop drugs that treat diabetes and obesity. Merck will commit up to $250 million to fund all of NGM’s efforts under the initial five-year term of the collaboration, with the potential for additional ...
Read More


MRK's price was unchanged after the transaction was announced on 02/23/15.
Investor / Buyer
Merck & Co. Inc.
 
Announced 02/1/15
Merck & Co. Inc., Merck Manufacturing Facility in Barceloneta, Puerto Rico
Merger/Acquisition

Merial Limited agreed to acquire the Merck manufacturing facility in Barceloneta, Puerto Rico from Merck & Co. Inc. (NYSE:MRK) on December 4, 2014. The proposed transaction requires approval from the United States Federal Trade Commission. If approved, the acquisition will allow Merial to expand its global manufacturing operations and make use of the site's expertise in chewables manufacturing technology. As part of the agreement, Merial will retain the approximately ...
Read More


MRK's price was unchanged after the transaction was announced on 02/1/15.
Investor / Buyer
Merial Limited
Creditor / Lender
Merck & Co. Inc.
 
Announced 12/18/14
375.00M for Oncoethix SA
Merger/Acquisition

Merck & Co. Inc. (NYSE:MRK) acquired OncoEthix SA from Index Ventures, Edmond de Rothschild Investment Partners, S.A.S., Endeavour II of Endeavour Vision SA, SV Life Sciences Advisers, LLC, and others for approximately $380 million on December 18, 2014. Under the terms of transaction, Merck shall make an upfront payment of up to $110 million to OncoEthix. Additional milestone payments of up to $265 million are contingent upon certain clinical and regulatory events being ...
Read More


MRK's price was unchanged after the transaction was announced on 12/18/14.
Investor / Buyer
Merck & Co. Inc.
Creditor / Lender
BioDiscovery 4 FCPR
Edmond de Rothschild Investment Partners, S.A.S.
Endeavour II
Endeavour Vision SA
Index Ventures
SV Life Sciences Advisers, LLC
 
Announced 12/8/14
9.09B for Cubist Pharmaceuticals Inc.
Merger/Acquisition

Merck & Co. Inc. entered into a definitive agreement to acquire Cubist Pharmaceuticals Inc. (NasdaqGS:CBST) from Bellevue Asset Management AG, Deutsche Asset & Wealth Management Investment GmbH, Federated Equity Management Company of Pennsylvania, HBM Partners Ltd.,Tekla Healthcare Investors and Tekla Life Sciences Investors, funds of Tekla Capital Management LLC, and others for $7.8 billion in cash on December 8, 2014. Merck will acquire the shares of Cubist for $102 ...
Read More


MRK's price was unchanged after the transaction was announced on 12/8/14.
Investor / Buyer
Merck & Co. Inc.
Creditor / Lender
Bellevue Asset Management AG
Deutsche Asset & Wealth Management Investment GmbH
Federated Equity Management Company of Pennsylvania
HBM Partners Ltd.
Tekla Capital Management LLC
Tekla Healthcare Investors
Tekla Life Sciences Investors
Financial Advisor
Goldman, Sachs & Co.
Morgan Stanley & Co. LLC
Legal Advisor
Cravath, Swaine & Moore LLP
Ropes & Gray LLP
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:US $58.58 USD +0.04

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $103.83 USD +0.30
GlaxoSmithKline PLC 1,554 GBp +12.50
Pfizer Inc $34.77 USD +0.45
Roche Holding AG SFr.261.00 CHF +2.20
Sanofi €86.40 EUR -1.30
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 14.4x
Price/Sales 4.0x
Price/Book 3.4x
Price/Cash Flow 14.0x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.